LONDON - ImmuPharma plc took $15 million up front as the first payment in a potential $500 million deal, as it signed an agreement giving Cephalon Inc. the option on an exclusive, worldwide license to Lupuzor in the treatment of systemic lupus erythematosus. (BioWorld International)